No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Established in 2010 and headquartered in Linhai, China, Zhejiang Ausun Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of unique active pharmaceutical ingredients (APIs) and various intermediate compounds for drug synthesis. Its comprehensive portfolio includes fluorine-based compounds, prostaglandins, and anti-infectives, in addition to critical oncology therapeutics. The company also provides medications targeting liver, respiratory, cardiovascular, and cerebrovascular conditions, as well as central nervous system (CNS) disorders. Furthermore, Zhejiang Ausun Pharmaceutical is involved in contract processing services and continuous scientific research and development initiatives.
www.ausunpharm.comNo one on the platform currently holds 603229.SS.
No tracked institution reports a position in 603229.SS as of their last filing.
No one on the platform has traded 603229.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.7% | 16.1% | 17.0% | — | — | — |
| Rev. Growth % | -1.1% | 14.0% | ||||
| Profit Margin % | 16.6% | 26.0% | 23.9% | |||
| Free Cash Flow Margin % | 6.6% | -4.3% | 0.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.2B | +23.7% | $0.40 | $0.40–$0.40 | — | 1 |
| 2027 | $1.2B | +0.0% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 603229.SSZhejiang Ausun Pharmaceutical Co., Ltd. | $7.59 | +0.53% | $6.3B | — |
| 000990.SZChengzhi Shareholding Co., Ltd. | $6.37 | -1.55% | $10.8B | — |
| 002030.SZDaan Gene Co., Ltd. | $5.27 | +0.96% | $7.4B | — |
| 002275.SZGuilin Sanjin Pharmaceutical Co., Ltd. | $12.11 | -0.08% | $7.1B | — |
| 300705.SZHunan Jiudian Pharmaceutical Co., Ltd. | $10.54 | +0.96% | $5.3B | — |
| 300725.SZPharmaBlock Sciences (Nanjing), Inc. | $46.37 |
Source: Financial Modeling Prep · peers by sector/industry
| +1.80% |
| $10.8B |
| — |
| 300841.SZChengdu Kanghua Biological Products Co., Ltd. | $50.37 | +1.65% | $6.5B | — |